Moderna Therapeutics said it has no intention to go public in the near term after securing $110 million in its latest equity funding round. The Cambridge, Mass.-based firm, which is focused on developing injectable messenger RNA molecules that trigger the body to produce therapeutic proteins, has secured $415 million in funding and development deals to date. The support "will enable us to strike the right balance between urgency and care to build a durable scientific platform and propel the field forward, without the short-term distractions that can side-track a young public company from its mission," Moderna CEO Stephane Bancel said.

Related Summaries